Compass Therapeutics (CMPX) Stock Price, News & Analysis

Company Overview

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB. The therapy is designed to stimulate immune cells involved in tumor recognition and destruction and has been investigated in combination with other immuno-oncology treatments. The company has also pursued additional antibody programs intended to modulate immune signaling and support the development of combination therapies.

Headquartered in Boston, Massachusetts, Compass Therapeutics conducts research and development activities primarily in the United States. As a clinical-stage company, its programs remain under development and may require additional clinical testing and regulatory review before any product can be commercialized.

Key Stats

• Today's Range: $0.83 to $0.85
• 50-Day Range: $0.86 to $2.53
• 52-Week Range: $0.83 to $6.88
• Volume: 90,086 shs
• Average Volume: 4.72 million shs
• Market Capitalization: $153.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.25
• Consensus Rating: Moderate Buy

Compass Therapeutics Stock Analysis - MarketRank™

Compass Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 73rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Compass Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Compass Therapeutics has a consensus price target of $10.25, representing about 1,124.6% upside from its current price of $0.84.

Amount of Analyst Coverage

Compass Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compass Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compass Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compass Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.56% of the float of Compass Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Compass Therapeutics has a short interest ratio ("days to cover") of 6.26.

Change versus previous month

Short interest in Compass Therapeutics has recently decreased by 3.10%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compass Therapeutics does not currently pay a dividend.

Dividend Growth

Compass Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.89

News Sentiment

Compass Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Compass Therapeutics this week, compared to 4 articles on an average week.

Search Interest

13 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

7 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $21,250.00 in company stock, which represents 0.0141% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,250.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.70% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CMPX
• CIK: 1738021
• Web: www.compasstherapeutics.com
• Phone: 617-500-8099
• Fax: N/A
• Employees: 39
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Compass Therapeutics: $10.25
• High Price Target: $30.00
• Low Price Target: $4.00
• Potential Upside/Downside: +1,101.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.71%
• Return on Assets: -34.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.22
• Quick Ratio: 11.22

Sales & Book Value

• Annual Sales: $850 thousand
• Price / Sales: 180.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.11 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 180,090,000
• Free Float: 146,412,000
• Market Cap: $153.62 million
• Optionable: Not Optionable
• Beta: 1.02